Although it may seem paradoxical, our results suggested that SLC25, and in particular, SLC25A5 and SLC25A24, might be involved in the EGFR and ERK-MAPK signaling pathways in colon cancer and potentially serve as treatment targets. This evidence concerns the gene SLC25A5 and malignant colon neoplasm.